Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.

Hunter BD, Rogalski M, Jacobson CA.

Expert Opin Biol Ther. 2019 Jul 25:1-8. doi: 10.1080/14712598.2019.1644316. [Epub ahead of print]

PMID:
31342797
2.

Redefining Non-Hodgkin Lymphoma: Using Genomic Subtypes to Improve Treatment Options.

Jacobson CA.

Hematol Oncol Clin North Am. 2019 Aug;33(4):xiii-xiv. doi: 10.1016/j.hoc.2019.04.005. Epub 2019 May 15. No abstract available.

PMID:
31229166
3.

Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.

Hunter BD, Chen YB, Jacobson CA.

Hematol Oncol Clin North Am. 2019 Aug;33(4):687-705. doi: 10.1016/j.hoc.2019.03.005. Epub 2019 May 10. Review.

PMID:
31229163
4.

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.

Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia & Lymphoma Society.

Lancet Haematol. 2019 Aug;6(8):e419-e428. doi: 10.1016/S2352-3026(19)30104-8. Epub 2019 Jun 14.

PMID:
31208944
5.

Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming.

Wang H, Sheehan RP, Palmer AC, Everley RA, Boswell SA, Ron-Harel N, Ringel AE, Holton KM, Jacobson CA, Erickson AR, Maliszewski L, Haigis MC, Sorger PK.

Cell Syst. 2019 May 22;8(5):412-426.e7. doi: 10.1016/j.cels.2019.03.009. Epub 2019 May 8.

6.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.

Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR.

Blood Adv. 2019 Apr 9;3(7):1167-1174. doi: 10.1182/bloodadvances.2018030221.

7.

PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.

Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF.

Blood. 2019 Jul 4;134(1):22-29. doi: 10.1182/blood.2019000215. Epub 2019 Apr 5.

PMID:
30952672
8.

Neurological toxicities associated with chimeric antigen receptor T-cell therapy.

Rubin DB, Danish HH, Ali AB, Li K, LaRose S, Monk AD, Cote DJ, Spendley L, Kim AH, Robertson MS, Torre M, Smith TR, Izzy S, Jacobson CA, Lee JW, Vaitkevicius H.

Brain. 2019 May 1;142(5):1334-1348. doi: 10.1093/brain/awz053.

PMID:
30891590
9.

Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.

Acharya UH, Dhawale T, Yun S, Jacobson CA, Chavez JC, Ramos JD, Appelbaum J, Maloney DG.

Expert Rev Hematol. 2019 Mar;12(3):195-205. doi: 10.1080/17474086.2019.1585238. Epub 2019 Mar 18.

PMID:
30793644
10.

CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions.

Hunter BD, Jacobson CA.

J Natl Cancer Inst. 2019 Feb 11. doi: 10.1093/jnci/djz017. [Epub ahead of print]

PMID:
30753567
11.

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.

Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, Jacobsen ED, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia and Lymphoma Society.

Lancet Haematol. 2019 Jan;6(1):e38-e47. doi: 10.1016/S2352-3026(18)30196-0. Epub 2018 Dec 14.

PMID:
30558987
12.

CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma.

Jacobson CA.

J Clin Oncol. 2019 Feb 1;37(4):328-335. doi: 10.1200/JCO.18.01457. Epub 2018 Dec 13.

PMID:
30557517
13.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS.

Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.

PMID:
30518502
14.

Immunotherapy in aggressive B-cell lymphomas.

Jacobson CA, Armand P.

Best Pract Res Clin Haematol. 2018 Sep;31(3):299-305. doi: 10.1016/j.beha.2018.07.015. Epub 2018 Jul 23. Review.

PMID:
30213400
15.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM.

Lancet Haematol. 2018 Nov;5(11):e563-e598. doi: 10.1016/S2352-3026(18)30051-6. Epub 2018 Jun 18. Review. Erratum in: Lancet Haematol. 2019 Mar;6(3):e121.

16.

Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.

Sun L, Li S, El-Jawahri A, Armand P, Dey BR, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, McAfee SL, Spitzer TR, Chen YB, DeFilipp Z.

Oncologist. 2018 May;23(5):624-630. doi: 10.1634/theoncologist.2017-0499. Epub 2017 Dec 28.

17.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY.

N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.

18.

Creating a System of Consistent Safety in the Froedtert & Medical College of Wisconsin Health Network.

Jacobson CA, Huerta S, Truwit J.

J Healthc Manag. 2017 Nov/Dec;62(6):366-370. doi: 10.1097/JHM-D-17-00158. No abstract available.

PMID:
29135760
19.

Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP).

Klein BD, Jacobson CA, Metcalf CS, Smith MD, Wilcox KS, Hampson AJ, Kehne JH.

Neurochem Res. 2017 Jul;42(7):1939-1948. doi: 10.1007/s11064-017-2287-8. Epub 2017 May 6.

PMID:
28478594
20.

Provider-Sponsored Health Plans: A Tool for Moving Toward Value-Based Reimbursement.

Jacobson CA.

Front Health Serv Manage. 2016 Fall;33(1):40-46. No abstract available.

PMID:
28199284
21.

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P.

J Clin Oncol. 2017 Jan;35(1):24-31. Epub 2016 Oct 24.

22.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. No abstract available.

23.

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR.

Blood. 2016 Jul 14;128(2):195-203. doi: 10.1182/blood-2016-03-707133. Epub 2016 May 31.

24.

Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant.

Mason EF, Brown RD, Szeto DP, Gibson CJ, Jia Y, Garcia EP, Jacobson CA, Dal Cin P, Kuo FC, Pinkus GS, Lindeman NI, Sholl LM, Aster JC, Morgan EA.

Leuk Lymphoma. 2017 Jan;58(1):233-236. Epub 2016 May 31. No abstract available.

PMID:
27241017
25.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Apr 11;29(4):574-586. doi: 10.1016/j.ccell.2016.03.008. Erratum in: Cancer Cell. 2016 Jul 11;30(1):183.

26.

Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma.

Jacobson CA, Freedman AS.

Curr Hematol Malig Rep. 2016 Jun;11(3):218-23. doi: 10.1007/s11899-016-0321-6. Review.

PMID:
26995595
27.

Rethinking Prognosis and Therapy for Follicular Lymphoma.

Jacobson CA, Freedman AS.

J Clin Oncol. 2015 Aug 10;33(23):2489-91. doi: 10.1200/JCO.2015.62.3256. Epub 2015 Jul 13. No abstract available.

PMID:
26169620
28.

Platelet-rich plasma does not decrease blood loss in total knee arthroplasty.

Tingstad EM, Bratt SN, Hildenbrand KJ, O'Malley BA, Mitchell ER, Gaddis CE, Jacobson CA.

Orthopedics. 2015 May;38(5):e434-6. doi: 10.3928/01477447-20150504-63.

PMID:
25970373
29.

Is observation dead in follicular lymphoma? Still appropriate.

Jacobson CA, Freedman AS.

J Natl Compr Canc Netw. 2015 Mar;13(3):367-70. Review.

PMID:
25736012
30.

Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.

Jacobson CA, Sun L, Kim HT, McDonough SM, Reynolds CG, Schowalter M, Koreth J, Cutler CS, Ho VT, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Ritz J, Sarantopoulos S.

Biol Blood Marrow Transplant. 2014 May;20(5):668-75. doi: 10.1016/j.bbmt.2014.01.021. Epub 2014 Jan 23.

31.

One size does not fit all in follicular lymphoma.

Jacobson CA, Freedman AS.

J Clin Oncol. 2013 Sep 20;31(27):3307-8. doi: 10.1200/JCO.2013.50.0454. Epub 2013 Aug 19. No abstract available.

PMID:
23960176
32.

First-line treatment of indolent lymphoma: axing CHOP?

Jacobson CA, Freedman AS.

Lancet. 2013 Apr 6;381(9873):1163-5. doi: 10.1016/S0140-6736(12)61965-5. Epub 2013 Feb 20. No abstract available.

PMID:
23433738
33.

Early stage follicular lymphoma, current management and controversies.

Jacobson CA, Freedman AS.

Curr Opin Oncol. 2012 Sep;24(5):475-9. doi: 10.1097/CCO.0b013e328356898b. Review.

PMID:
22820411
34.

HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART.

Jacobson CA, Abramson JS.

Adv Hematol. 2012;2012:507257. doi: 10.1155/2012/507257. Epub 2012 Jan 5.

35.

Follicular lymphoma: to treat or not to treat is no longer the question.

Jacobson CA, Longo DL.

J Natl Cancer Inst. 2012 Jan 4;104(1):3-5. doi: 10.1093/jnci/djr498. Epub 2011 Dec 21. No abstract available.

PMID:
22190632
36.

Time to put the CAR-T before the horse.

Jacobson CA, Ritz J.

Blood. 2011 Nov 3;118(18):4761-2. doi: 10.1182/blood-2011-09-376137. No abstract available.

37.

Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.

Jacobson CA, Turki AT, McDonough SM, Stevenson KE, Kim HT, Kao G, Herrera MI, Reynolds CG, Alyea EP, Ho VT, Koreth J, Armand P, Chen YB, Ballen K, Soiffer RJ, Antin JH, Cutler CS, Ritz J.

Biol Blood Marrow Transplant. 2012 Apr;18(4):565-74. doi: 10.1016/j.bbmt.2011.08.018. Epub 2011 Aug 26.

38.

Lymphoma: risk and response after solid organ transplant.

Jacobson CA, LaCasce AS.

Oncology (Williston Park). 2010 Sep;24(10):936-44. Review.

39.

B-cell-directed therapy for chronic graft-versus-host disease.

Jacobson CA, Ritz J.

Haematologica. 2010 Nov;95(11):1811-3. doi: 10.3324/haematol.2010.032227. No abstract available.

40.

A competitive advantage in the capital market.

Jacobson CA.

Hosp Health Netw. 2009 May;83(5):suppl 11. No abstract available.

PMID:
19580091
41.

Planning during turmoil: credit challenges and healthcare finance. Interview by Carole J. Bolster.

Bigalke JT, Goldstein L, Gourdon C, Jacobson CA, Kaufman K, Long RR.

Healthc Financ Manage. 2008 Nov;62(11):54-62.

PMID:
18990837
42.

Unusual uterine recurrence of primary central nervous system lymphoma.

Nichols GL, Jacobson CA, Ferman D, Lichtman SM.

Clin Adv Hematol Oncol. 2006 Sep;4(9):697-8, discussion 699-700. No abstract available.

PMID:
17099627
43.

Auditory brainstem response detects early bilirubin neurotoxicity at low indirect bilirubin values.

Smith CM, Barnes GP, Jacobson CA, Oelberg DG.

J Perinatol. 2004 Nov;24(11):730-2.

PMID:
15510103
44.

Development of highly selective SH3 binding peptides for Crk and CRKL which disrupt Crk-complexes with DOCK180, SoS and C3G.

Posern G, Zheng J, Knudsen BS, Kardinal C, Müller KB, Voss J, Shishido T, Cowburn D, Cheng G, Wang B, Kruh GD, Burrell SK, Jacobson CA, Lenz DM, Zamborelli TJ, Adermann K, Hanafusa H, Feller SM.

Oncogene. 1998 Apr 16;16(15):1903-12.

45.

The effects of noise in transient EOAE newborn hearing screening.

Jacobson JT, Jacobson CA.

Int J Pediatr Otorhinolaryngol. 1994 Jun;29(3):235-48.

PMID:
8056507
46.

Automated and conventional ABR screening techniques in high-risk infants.

Jacobson JT, Jacobson CA, Spahr RC.

J Am Acad Audiol. 1990 Oct;1(4):187-95.

PMID:
2132603
47.

Follow-up services in newborn hearing screening programs.

Jacobson CA, Jacobson JT.

J Am Acad Audiol. 1990 Oct;1(4):181-6.

PMID:
2132602
48.

Hearing loss in prison inmates.

Jacobson CA, Jacobson JT, Crowe TA.

Ear Hear. 1989 Jun;10(3):178-83.

PMID:
2744254
49.

THE ECR IS PROGRESSING.

Jacobson CA.

Science. 1941 Mar 21;93(2412):280-1. No abstract available.

PMID:
17834794
50.

THE ENCYCLOPEDIA OF CHEMICAL REACTIONS.

Jacobson CA.

Science. 1941 Jan 17;93(2403):61. No abstract available.

PMID:
17832853

Supplemental Content

Loading ...
Support Center